Innovent Biologics HKEX:1801 has entered into an agreement that grants it sole commercialization rights for Eli Lilly's NYSE:LLY breast cancer drug Verzenios in mainland China, the Chinese drugmaker said Tuesday.

Lilly will continue manufacturing, supplying and developing the drug, it said in a statement.